Clinical Trial Update: Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 trial evaluating Copper-64 TP3805 PET/CT imaging for bladder urothelial carcinoma in patients undergoing surgery or biopsy. The study has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Urothelial Carcinoma

Drugs mentioned

• Cu-64 TP3805 (Copper-64 TP3805)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Bladder Urothelial Carcinoma, Urothelial Carcinoma | EARLY_Phase 1 | Status: COMPLETED